Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses

International Journal of Oncology

Volumn 38, Issue 4, 2011, Pages 911-919

  Negoro, Eiju ^a   Yamauchi, Takahiro ^a   Urasaki, Yoshimasa ^a   Nishi, Rie ^a   Hori, Hiroki ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ara C; DNA microarray analysis; Leukemia; Proteome analysis; Resistance

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; DEOXYCYTIDINE KINASE; GEMCITABINE; IRINOTECAN; MITOXANTRONE; NUCLEOTIDASE; STATHMIN; VINCRISTINE;

AKT1 GENE; ARTICLE; C19ORF2 GENE; CACNA2D3 GENE; CELL CLONE; CELL LEVEL; CELL LINEAGE; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HSPA8 GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LGALS1 GENE; MBC2 GENE; MEMBRANE TRANSPORT; POU4F3 GENE; PRIORITY JOURNAL; PROTEOMICS; PSAP GENE;

5'-NUCLEOTIDASE; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL LINEAGE; CELL SURVIVAL; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME ASSAYS; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; LEUKEMIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME;

EID: 79952321197     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.933     Document Type: Article

References (46)

1. Cheson BD: New antimetabolites in the treatment of human malignancies. Semin Oncol 19: 695-706, 1992.
2. Garcia-Carbonero R, Ryan DP and Chabner BA: Cytidine analogs. In: Cancer Chemotherapy and Biotherapy. Chabner BA and Longo DL (eds). Lippincott-Raven Publishers, Philadelphia, pp265-294, 1996.
3. Blum W and Marcucci G: New approaches in acute myeloid leukemia. Best Pract Res Clin Haematol 21: 29-41, 2008. (Pubitemid 351377512)
4. Tallman MS, Gilliland DG and Rowe JM: Drug therapy for acute myeloid leukemia. Hood 106: 1154-1163, 2005. (Pubitemid 41130866)
5. Fernandez HF and Rowe JM: Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol 17: 79-84, 2010.
6. Wiley JS, Jones SP, Sawyer WH and Paterson AR: Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69: 479-489, 1982.
7. Galmarini CM, Jordheim L and Dumontet C: Role of IMP-selective 5′-nucleotidase (cN-II) in hematological malignancies. Leuk Lymphoma 44: 1105-1111, 2003. (Pubitemid 36609103)
8. Kufe DW, Major PP, Egan EM and Beardsley GP: Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255: 8997-9990, 1980.
9. Kufe D, Spriggs D, Egan EM and Munroe D: Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64: 54-58, 1984. (Pubitemid 14085726)
10. Huang P and Plunkett W: Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36: 181-188, 1995.
11. Yamauchi T, Ueda T and Nakamura T: A new sensitive method for determination of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate content in human materials in vivo. Cancer Res 56: 1800-1804, 1996.
12. Yamauchi T, Kawai Y, Kishi S, et al: Monitoring of intracellular 1-β-D-arabinofuranosylcytosine 5′-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low- and conventional-doses. Cancer Sci 92: 546-553, 2001. (Pubitemid 32515096)
13. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO and Kealing MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12 (Suppl. 3): S20-S30, 1985.
14. Plunkett W, Liliemark JO, Adams TM, et al: Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 47: 3005-3011, 1987. (Pubitemid 17113452)
15. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al: Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 106: 78-85, 1999. (Pubitemid 29343530)
16. Lotfi K, Månsson E, Chandra J, et al: Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br J Haematol 113: 339-346, 2001. (Pubitemid 32523136)
17. Gandhi V, Estey E, Keating MJ and Plunkett W: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11: 116-124, 1993. (Pubitemid 23059984)
18. Estey E, Thall P, Andreeff M, et al: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671-678, 1994.
19. Yue L, Saikawa Y, Ota K, et al: A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13: 29-38, 2003. (Pubitemid 36135684)
20. Yamauchi T, Negoro E, Kishi S, et al: Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 77: 1780-1786, 2009.
21. Yong AS and Melo JV: The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22: 181-190, 2009.
22. Kaneta Y, Kagami Y, Katagiri T, et al: Prediction of sensitivity to ST1571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Cancer Sci 93: 849-856, 2002.
23. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 28: 596-604, 2010.
24. Yamamoto S, Yamauchi T, Kawai Y, et al: Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells. Int J Hematol 85: 108-115, 2007. (Pubitemid 46365546)
25. Yoshio N, Kawai Y, Hori H and Ueda T: Resistance to 9-beta-D- arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. Int J Hematol 81: 405-412, 2005. (Pubitemid 40917683)
26. Wei W, Dorjsuren D, Lin Y, et al: Direct interaction between the subunit RAP30 of transcription factor HF (TFIIF) and RNA polymerase subunit 5, which contributes to the association between TFIIF and RNA polymerase II. J Biol Chem 276: 12266-12273, 2001.
27. Craig EA, Weissman JS and Horwich AL: Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell 78: 365-372, 1994. (Pubitemid 24250802)
28. Dhirapong A, Lleo A, Leung P, Gershwin ME and Liu FT: The immunological potential of galectin-1 and -3. Autoimmun Rev 8: 360-363, 2009.
29. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D and Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res 70: 2718-2727, 2010.
30. Kang SY, Halvorsen OJ, Gravdal K, et al: Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci USA 106: 12115-12120, 2009.
31. Santi SA and Lee H: The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol 298: C580-C591, 2010.
32. Lalioti V, Muruais G, Dinarina A, van Damme J, Vandekerckhove J and Sandoval IV: The atypical kinase Cdk5 is activated by insulin, regulates the association between GLUT4 and E-Syt1, and modulates glucose transport in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 106: 4249-4253, 2009.
33. Wanajo A, Sasaki A, Nagasaki H, et al: Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology 135: 580-590, 2008.
34. Jeon TY, Han ME, Lee YW et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 102: 710-718, 2010.
35. Hsieh SY, Huang SF, Yu MC, et al: Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 49: 476-487, 2010.
36. Takemura H, Urasaki Y, Yoshida A, Fukushima T and Ueda T: Multaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res 61: 172-177, 2001. (Pubitemid 32095715)
37. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828-1837, 2004.
38. Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133-143, 2002. (Pubitemid 41039160)
39. Takagaki K, Katsuma S, Horio T, et al: cDNA microarray analysis of altered gene expression in ara-C-treated leukemic cells. Biochem Biophys Res Commun 309: 351-358, 2003. (Pubitemid 37025899)
40. Abe S, Funato T, Takahashi S, et al: Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209: 217-228, 2006. (Pubitemid 43905553)
41. Song JH, Kim SH, Kweon SH, et al: Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol 34: 1165-1171, 2009.
42. Lee IN, Chen CH, Sheu JC, et al: Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. Proteome Res 4: 2062-2069, 2005.
43. Bhojwani D, Moskowitz N, Raetz EA and Carroll WL: Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. Paediatr Drugs 9: 149-156, 2007. (Pubitemid 46849134)
44. Czibere A, Grall F and Aivado M: Perspectives of proteomics in acute myeloid leukemia. Expert Rev Anticancer Ther 6: 1663-1675, 2006. (Pubitemid 44888566)
45. Oishi Y, Nagasaki K, Miyata S, et al: Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 52: 271-279, 2007.
46. Chung MK, Kim HJ, Lee YS, et al: Hedgehog signaling regulates proliferation of prostate cancer cells via stathminl. Clin Exp Med 10: 51-57, 2010.